Google-backed AI drug discovery company XtalPi and JW C&C Research Laboratories (JW C&C), a subsidiary of JW Pharmaceutical, have entered an agreement to develop immune-targeting small-molecular therapeutics. The terms and financial details of the agreement have not been disclosed.
The partnership will leverage Xtalpi’s AI drug development platform and automated systems to enhance lead compounds targeting the STAT6 protein, a regulator of the inflammatory immune reaction in type 2 helper T-cells (Th2).
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.